-transparent.png){kind=logo}
The 2-hydroxylation of desmethylimipramine (DMI) correlates strongly with the 4-hydroxylation of debrisoquine (D) both in human volunteers and in vitro comparing human liver microsomes from different individuals. D competitively inhibits the 2-hydroxylation of DMI in vitro suggesting that DMI is hydroxylated by the 'debrisoquine hydroxylase' which is under monogenic control in man. We have characterized the effect of drugs on the hydroxylation of DMI in human liver microsomes by measuring the formation of 2-OH-DMI with HPLC using fluorescence detection. Amitriptyline, nortriptyline and metoprolol inhibited the hydroxylation of DMI competitively indicating interaction with the catalytical site for DMI 2-hydroxylation. Antipyrine and amylobarbitone at concentrations similar to their Km-values for metabolism did not inhibit DMI-hydroxylation. Thus, for these compounds there was a good correspondence between the drugs' capacity to inhibit DMI 2-hydroxylation competitively in vitro and their apparent metabolism by the 'debrisoquine hydroxylase' in vivo in man. Thioridazine, chlorpromazine, quinidine and quinine also inhibited DMI-hydroxylation competitively. Thioridazine was an unusually potent inhibitor (apparent inhibition constant Ki = 0.75 microM). Quinidine was also an unusually potent inhibitor (Ki = 0.27 microM) and much more efficient than its isomer quinine (Ki = 12 microM). Theophylline could inhibit DMI hydroxylation but with atypical kinetics. We suggest that this simple DMI in vitro test as well as earlier described inhibition tests with debrisoquine, sparteine and bufuralol can be used to screen if drugs interact with the 'debrisoquine hydroxylase' in human liver.
C von Bahr, and
E Spina, and
C Birgersson, and
O Ericsson, and
M Göransson, and
T Henthorn, and
F Sjöqvist
May 1971,
Xenobiotica; the fate of foreign compounds in biological systems,
C von Bahr, and
E Spina, and
C Birgersson, and
O Ericsson, and
M Göransson, and
T Henthorn, and
F Sjöqvist
January 1986,
European journal of clinical pharmacology,
C von Bahr, and
E Spina, and
C Birgersson, and
O Ericsson, and
M Göransson, and
T Henthorn, and
F Sjöqvist
January 1994,
Drug metabolism and disposition: the biological fate of chemicals,
C von Bahr, and
E Spina, and
C Birgersson, and
O Ericsson, and
M Göransson, and
T Henthorn, and
F Sjöqvist
January 1972,
Steroids and lipids research,
C von Bahr, and
E Spina, and
C Birgersson, and
O Ericsson, and
M Göransson, and
T Henthorn, and
F Sjöqvist
December 1961,
Experientia,
C von Bahr, and
E Spina, and
C Birgersson, and
O Ericsson, and
M Göransson, and
T Henthorn, and
F Sjöqvist
September 1972,
FEBS letters,
C von Bahr, and
E Spina, and
C Birgersson, and
O Ericsson, and
M Göransson, and
T Henthorn, and
F Sjöqvist
June 1967,
Biochemistry,
C von Bahr, and
E Spina, and
C Birgersson, and
O Ericsson, and
M Göransson, and
T Henthorn, and
F Sjöqvist
March 2000,
Drug metabolism and disposition: the biological fate of chemicals,
C von Bahr, and
E Spina, and
C Birgersson, and
O Ericsson, and
M Göransson, and
T Henthorn, and
F Sjöqvist
January 1974,
Acta pharmacologica et toxicologica,
C von Bahr, and
E Spina, and
C Birgersson, and
O Ericsson, and
M Göransson, and
T Henthorn, and
F Sjöqvist
January 1989,
Drug metabolism and disposition: the biological fate of chemicals,
